Statin therapy in primary prevention
What is new?
Listen to Prof. Nordestgaard explain the new recommendations on statin therapy. The update provides clear guidance on primary prevention with statins, outlining:
- The role of statins in preventing future cardiovascular events
- Who should or may be considered for statin therapy in primary prevention
- How treatment can be offered to individuals currently free of cardiovascular disease
Recommendations for statin therapy in primary prevention
| Recommendations | Classa | Levelb |
| In primary prevention, pharmacological LDL-C-lowering therapy is recommended in persons: – at very high risk and LDL-C ≥1.8 mml/L (70 mg/dL), or – at high risk and LDL-C ≥2.6 mmol/L (100mg/dL) despite optimization of non-pharmacological measures, to lower CVD risk. | I | A |
| In primary prevention, pharmacological LDL-C-lowering therapy should be considered in persons: – at very high risk and LDL-C ≥1.4 mmol/L (55mg/dL) but <1.8 mmol/L (70 mg/dL), or – at high risk and LDL-C ≥1.8 mmol/L (70 mg/dL) but 2.6 mmol/L (100mg/dL), or – at moderate risk and LDL-C ≥2.6 mmol/L (100mg/dL) but <4.9 mmol/L (190 mg/dL), or – at low risk and LDL-C ≥ 3.0 mmol/L (116 mg/dL) but <4.9 mmol/L (190 mg/dL) despite optimization of non-pharmacological measures, to lower CVD risk. | IIa | A |